Sign up Australia
Proactive Investors - Run By Investors For Investors

Pharmaxis has key drivers in place for short and long term value creation

Pharmaxis Ltd (ASX:PXS) chief executive Gary Phillips speaks to Proactive Investors about the pharmaceutical research company’s business model and value drivers, and provides some context about the sector, which is seeing a lot of headline-grabbing merger and acquisition activity.

"I think there's three things about our company that make us a little bit different from some of our peer group. I think the number one is that we have cash... secondly, the team that we've grown... and lastly,  I think, our portfolio... Pharmaxis isn't a company where we've just got one program; an investment in us isn't like putting money on black or red on a roulette table. We understand that early biotech companies [carry] a fair amount of risk and some programs may fall over, but we have a portfolio of drugs on the market, drugs that are already partnered, and drugs that are still in development," says Phillips.

Pharmaxis is in talks for a partnership deal on its LOXL2 anti‐fibrotic program, with hopes of announcing a partner in the second half of this year. Trial results from the Boehringer Ingelheim partnered program, which will potentially demonstrate proof of concept in patients for two indications, are expected out in the first half of next year.

 
Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event, Sydney , 19 November 2018. Register here »
View full PXS profile View Profile

Pharmaxis Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use